In vitro and in vivo antifungal activities of BMS-181184.
Oki
T
T
Bristol-Myers Squibb Research Institute, Bristol-Myers Squibb K.K., Tokyo, Japan.
Kakushima
M
M
Hirano
M
M
Takahashi
A
A
Ohta
A
A
Masuyoshi
S
S
Hatori
M
M
Kamei
H
H
D000818:Animals; D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy*; D001232:Aspergillus fumigatus; D002177:Candidiasis / Q000188:drug therapy*; D003453:Cryptococcosis / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000627:therapeutic use; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D008826:Microbial Sensitivity Tests; D013329:Structure-Activity Relationship; D000095643:Pradimicins and Benanomicins
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D000935:Antifungal Agents; D003520:Cyclophosphamide; C058036:pradimicin A; D000095643:Pradimicins and Benanomicins; C077639:3'-hydroxybenanomicin A